AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate

✍ Scribed by Tanya J. Shaw; Barbara C. Vanderhyden

• Book ID: 113960899
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 782 KB
• Volume: 105
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2006.10.052